



## **bioMérieux receives CE-marking for VIDAS® VITAMIN B<sub>12</sub> TOTAL, a blood test to measure total Vitamin B<sub>12</sub> concentration**

**Marcy-l'Étoile, France, October 15<sup>th</sup>, 2024 – bioMérieux, a world leader in the field of *in vitro* diagnostics, announces the CE-marking of VIDAS® VITAMIN B<sub>12</sub> TOTAL, an automated quantitative test for use on the VIDAS® immunoassay instruments, for the measurement of total Vitamin B<sub>12</sub> concentration in human serum or plasma.**

Vitamin B<sub>12</sub>, also known as cobalamin, is essential for well-being and cellular metabolism. This micronutrient, mainly present in food products from animal origin – particularly meat, fish, eggs and dairy – is required for normal functioning of the central nervous system, DNA synthesis and healthy red blood cell formation.

Measuring levels of vitamin B<sub>12</sub> may help optimize patients' care since its deficiency can be associated with anemia or neurological symptoms including cognitive difficulties or impaired gait. VIDAS® VITAMIN B<sub>12</sub> TOTAL is an automated quantitative test to aid in the assessment of vitamin B<sub>12</sub> status in adults with suspected vitamin B<sub>12</sub> deficiency or at risk for low levels of vitamin B<sub>12</sub>.

This new assay is for use on all VIDAS® immunoanalysers that provide laboratory personnel with increased throughput and full traceability of test results. VIDAS® VITAMIN B<sub>12</sub> TOTAL completes the VIDAS® routine test menu, reinforcing the family of assays targeting anemia.

*“As it enters a fourth decade, VIDAS® remains a core focus of the bioMérieux immunoassay strategy with continued R&D investment in new product innovation. VIDAS® VITAMIN B<sub>12</sub> TOTAL perfectly complements our comprehensive VIDAS® portfolio that also includes infectious diseases, emergency, and critical care assays. The launch of VIDAS® VITAMIN B<sub>12</sub> TOTAL is a testament to bioMérieux's on-going commitment to provide value-add diagnostic solutions to lab and healthcare professionals for optimized patient care,”* commented Jennifer Zinn, Executive Vice President, Clinical Operations, bioMérieux.

The commercial launch of VIDAS® VITAMIN B<sub>12</sub> TOTAL is planned in select countries at the end of 2024, with an extended rollout in Q1 2025.

### **ABOUT VIDAS®**

Launched over 30 years ago, VIDAS® has transformed the field of immunoassays offering laboratories universal access to a simple, automated, and robust technology providing fast and safe results. Today, VIDAS® is still one of the most widely used immunoassay systems in clinical laboratories worldwide.

The VIDAS® menu comprises around 100 parameters, including infectious and chronic diseases, as well as a range of tests dedicated to emergency and critical care.

bioMérieux maintains ongoing commitment to the VIDAS® range, with continual research and new immunoassay solutions to create value for labs and clinicians, benefiting patient care.

PRESS RELEASE



## ABOUT BIOMÉRIEUX

### *Pioneering Diagnostics*

A world leader in the field of *in vitro* diagnostics since 1963, bioMérieux is present in 45 countries and serves more than 160 countries with the support of a large network of distributors. In 2023, revenues reached €3.7 billion, with over 90% of sales outside of France.

bioMérieux provides diagnostic solutions (systems, reagents, software and services) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are mainly used for diagnosing infectious diseases. They are also used for detecting microorganisms in food, pharmaceutical and cosmetic products.

[www.biomerieux.com](http://www.biomerieux.com).



bioMérieux is listed on the Euronext Paris stock market.

Symbol: BIM – ISIN Code: FR0013280286

Reuters: BIOX.PA/Bloomberg: BIM.FP

## CONTACTS

### Investor Relations

Aymeric Fichet

Tel.: +33 (0)4 78 87 20 00

[investor.relations@biomerieux.com](mailto:investor.relations@biomerieux.com)

### Media Relations

**bioMérieux**

Romain Duchez

Tel.: +33 (0)4 78 87 20 00

[media@biomerieux.com](mailto:media@biomerieux.com)

**UNITED STATES**

Liza Deckelbaum (SEEZ)

Tel. : (919) 521-0507

[lizad@seeztoday.com](mailto:lizad@seeztoday.com)

**FRANCE**

Laurence Heilbronn (Image 7)

Tel.: +33 (0)1 53 70 74 48

[lheilbronn@image7.fr](mailto:lheilbronn@image7.fr)

PRESS RELEASE